AstraZeneca PLC logo
AstraZeneca PLC (AZN)
Compare

AstraZeneca PLC (AZN) Dividend Yield: 1.79%

Is AstraZeneca PLC’s dividend yield high or low?

AstraZeneca PLC's dividend yield of 1.79% is 16% below its 5-year average of 2.14%, near the low end of its 5-year range (1.51%–4.18%).

As of Sunday, June 14, 2026. 3.42% below its 12-month average of 1.85%.

Dividend Yield (1.79%) = TTM Dividends/Share ($3.20) / Share Price ($178.75)

AZN Dividend Yield Chart

AZN Dividend Yield
1.79%-15.28% 1Y
Zoom
1.50%2.00%2.50%3.00%Jun 25Sep 25Dec 25Mar 26Jun 26

AZN Average Dividend Yield Chart

AZN Current vs Average Dividend Yield Chart

AZN Dividend Yield Metrics

DIVIDEND YIELD

1.79%

DIVIDEND YIELD AVG TTM

1.85%

DIVIDEND YIELD AVG 3Y

2.02%

DIVIDEND YIELD AVG 5Y

2.14%

DIVIDEND YIELD AVG 10Y

2.88%

DIVIDEND YIELD AVG 15Y

3.59%

DIVIDEND YIELD AVG 20Y

3.76%

CURRENT VS TTM AVG

-3.42%

CURRENT VS 3Y AVG

-11.58%

CURRENT VS 5Y AVG

-16.34%

CURRENT VS 10Y AVG

-37.93%

CURRENT VS 15Y AVG

-50.09%

CURRENT VS 20Y AVG

-52.38%

AZN Competitors' Dividend Yield

NAMEMARKET CAPDIVIDEND YIELDTTM3Y5Y
AstraZeneca PLC (AZN)$277.22B1.79%1.85%2.02%2.14%
Merck & Co., Inc. (MRK)vs ›$294.03B2.79%3.32%3.06%3.08%
Amgen Inc. (AMGN)vs ›$191.70B2.76%2.97%3.09%3.16%
UnitedHealth Group Incorporated (UNH)vs ›$371.00B2.16%2.24%1.82%1.62%
Thermo Fisher Scientific Inc. (TMO)vs ›$174.42B0.28%0.34%0.31%0.27%
Gilead Sciences, Inc. (GILD)vs ›$155.93B1.91%2.54%3.35%3.67%
Abbott Laboratories (ABT)vs ›$153.59B2.77%2.06%1.98%1.86%
AbbVie Inc. (ABBV)vs ›$402.35B2.96%3.10%3.50%3.71%
Pfizer Inc. (PFE)vs ›$149.38B6.56%6.70%6.18%5.10%
Intuitive Surgical, Inc. (ISRG)vs ›$145.58BN/AN/AN/AN/A

AstraZeneca PLC Dividend Yield Formula & Definition

Dividend yield is the trailing-12-month dividends per share divided by the share price — the cash income the stock pays at today's price. A yield far above a company's own history can signal either value or a market doubting the dividend; read it with the payout ratio.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

AstraZeneca PLC Dividend Yield FAQ

What is the dividend yield for AstraZeneca PLC (AZN)?
The dividend yield for AZN stock is 1.79%.
Is AstraZeneca PLC's dividend yield high or low?
AstraZeneca PLC's dividend yield of 1.79% is 16% below its 5-year average of 2.14%, near the low end of its 5-year range (1.51%–4.18%).
What is the TTM average dividend yield for AstraZeneca PLC (AZN)?
The TTM average dividend yield for AZN stock is 1.85%.
What is the 3Y average dividend yield for AstraZeneca PLC (AZN)?
The 3Y average dividend yield for AZN stock is 2.02%.
What is the 5Y average dividend yield for AstraZeneca PLC (AZN)?
The 5Y average dividend yield for AZN stock is 2.14%.
What is the 10Y average dividend yield for AstraZeneca PLC (AZN)?
The 10Y average dividend yield for AZN stock is 2.88%.
What is the 15Y average dividend yield for AstraZeneca PLC (AZN)?
The 15Y average dividend yield for AZN stock is 3.59%.
What is the 20Y average dividend yield for AstraZeneca PLC (AZN)?
The 20Y average dividend yield for AZN stock is 3.76%.

AstraZeneca PLC Dividend Yield History

DATEDIVIDEND YIELD
2026-06-121.79%
2026-06-101.79%
2026-06-081.76%
2026-06-041.76%
2026-06-021.80%
2026-05-291.72%
2026-05-271.72%
2026-05-221.71%
2026-05-201.71%
2026-05-181.74%
2026-05-141.73%
2026-05-121.73%
2026-05-081.75%
2026-05-061.73%
2026-05-041.74%
2026-04-301.71%
2026-04-281.71%
2026-04-241.69%
2026-04-221.64%
2026-04-201.59%
2026-04-161.60%
2026-04-141.57%
2026-04-101.57%
2026-04-081.57%
2026-04-061.58%
2026-04-011.59%
2026-03-301.65%
2026-03-261.74%
2026-03-241.72%
2026-03-201.74%
2026-03-181.70%
2026-03-161.67%
2026-03-121.66%
2026-03-101.64%
2026-03-061.65%
2026-03-041.59%
2026-03-021.57%
2026-02-261.57%
2026-02-241.55%
2026-02-202.61%
2026-02-181.51%
2026-02-131.54%
2026-02-111.54%
2026-02-091.68%
2026-02-051.69%
2026-02-031.71%
2026-01-301.69%
2026-01-281.68%
2026-01-261.76%
2026-01-221.76%
2026-01-201.72%
2026-01-151.67%
2026-01-131.67%
2026-01-091.65%
2026-01-071.66%
2026-01-051.76%
2025-12-311.80%
2025-12-291.69%
2025-12-241.69%
2025-12-221.75%
2025-12-181.75%
2025-12-161.73%
2025-12-121.76%
2025-12-101.74%
2025-12-081.75%
2025-12-041.75%
2025-12-021.76%
2025-11-281.72%
2025-11-251.68%
2025-11-211.73%
2025-11-191.76%
2025-11-171.80%
2025-11-131.78%
2025-11-111.80%
2025-11-071.90%
2025-11-051.95%
2025-11-031.95%
2025-10-301.92%
2025-10-281.91%
2025-10-241.93%
2025-10-221.89%
2025-10-201.89%
2025-10-161.87%
2025-10-141.87%
2025-10-101.86%
2025-10-081.84%
2025-10-061.83%
2025-10-021.92%
2025-09-302.11%
2025-09-262.16%
2025-09-242.12%
2025-09-222.01%
2025-09-182.06%
2025-09-162.06%
2025-09-121.98%
2025-09-101.97%
2025-09-081.94%
2025-09-041.95%
2025-09-021.97%
2025-08-282.00%
2025-08-261.97%
2025-08-222.01%
2025-08-202.00%
2025-08-181.97%
2025-08-142.03%
2025-08-122.13%
2025-08-082.93%
2025-08-062.10%
2025-08-042.08%
2025-07-312.12%
2025-07-292.08%
2025-07-252.15%
2025-07-232.12%
2025-07-212.24%
2025-07-172.26%
2025-07-152.23%
2025-07-112.23%
2025-07-092.21%
2025-07-072.19%
2025-07-022.17%
2025-06-302.24%
2025-06-262.24%
2025-06-242.22%
2025-06-202.24%
2025-06-172.22%
2025-06-132.11%
2025-06-112.11%
2025-06-092.13%
2025-06-052.19%
2025-06-032.20%
2025-05-302.21%
2025-05-282.22%
2025-05-232.18%
2025-05-212.26%
2025-05-192.22%
2025-05-152.30%
2025-05-132.31%
2025-05-092.31%
2025-05-072.26%
2025-05-052.14%
2025-05-012.22%
2025-04-292.16%
2025-04-252.32%
2025-04-232.30%
2025-04-212.36%
2025-04-162.33%
2025-04-142.38%
2025-04-102.43%
2025-04-082.36%
2025-04-042.29%
2025-04-022.12%
2025-03-312.12%
2025-03-272.23%
2025-03-252.12%
2025-03-212.04%
2025-03-192.03%
2025-03-172.02%
2025-03-132.03%
2025-03-112.11%
2025-03-072.02%
2025-03-051.99%
2025-03-032.07%
2025-02-272.08%
2025-02-252.07%
2025-02-212.20%
2025-02-192.05%
2025-02-142.00%
2025-02-122.03%
2025-02-101.99%
2025-02-061.96%
2025-02-042.13%
2025-01-312.11%
2025-01-292.13%
2025-01-272.14%
2025-01-232.19%
2025-01-212.19%
2025-01-162.25%
2025-01-142.24%
2025-01-102.19%
2025-01-072.25%
2025-01-032.26%
2024-12-312.28%
2024-12-272.25%
2024-12-242.27%
2024-12-202.24%
2024-12-182.29%
2024-12-162.26%
2024-12-122.24%
2024-12-102.21%
2024-12-062.20%
2024-12-042.28%
2024-12-022.19%
2024-11-272.20%
2024-11-252.26%
2024-11-212.36%
2024-11-192.36%
2024-11-152.32%
2024-11-132.30%
2024-11-112.34%
2024-11-072.35%
2024-11-052.27%
2024-11-012.08%
2024-10-301.99%
2024-10-281.95%
2024-10-241.96%
2024-10-221.90%
2024-10-181.88%
2024-10-161.90%
2024-10-141.90%
2024-10-102.02%
2024-10-082.00%
2024-10-041.95%
2024-10-021.87%
2024-09-301.91%
2024-09-261.90%
2024-09-241.99%
2024-09-201.91%
2024-09-181.81%
2024-09-161.89%
2024-09-121.90%
2024-09-101.85%
2024-09-061.76%
2024-09-041.75%
2024-08-301.70%
2024-08-281.71%
2024-08-261.70%
2024-08-221.75%
2024-08-201.75%
2024-08-161.75%
2024-08-141.79%
2024-08-121.85%
2024-08-081.75%
2024-08-061.90%
2024-08-021.77%
2024-07-311.82%
2024-07-291.86%
2024-07-251.87%
2024-07-231.81%
2024-07-191.88%
2024-07-171.82%
2024-07-151.86%
2024-07-111.89%
2024-07-091.88%
2024-07-051.95%
2024-07-021.87%
2024-06-281.86%
2024-06-261.83%
2024-06-241.91%
2024-06-201.91%
2024-06-171.83%
2024-06-131.82%
2024-06-111.80%
2024-06-071.81%
2024-06-051.81%
2024-06-031.83%
2024-05-301.89%
2024-05-281.83%
2024-05-231.82%
2024-05-211.82%
2024-05-171.87%

Showing the most recent 260 of 3,774 data points. The chart above shows the full history.

About AstraZeneca PLC

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Cambridge
94,300 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Pascal Claude Roland Soriot